Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
interim Phase 3 data for BBP-418, and outlining a new TTR amyloid depleter program. See our latest analysis for BridgeBio Pharma. The recent news flow, including Attruby uptake, interim Phase 3 BBP-418 data, and a planned US$550 million convertible notes offering alongside share repurchases, comes after a 90 day share price return of 41.56% and a very large 3 year total shareholder return. Together, these factors indicate momentum has been building despite some short term share price volatility. If Attruby and the late stage pipeline have caught your eye, it could be worth broadening your research to other healthcare stocks that are also moving on clinical and commercial updates. With BBIO up 41.56% in 90 days, trading at US$77.90 and flagged with a low value score of 2 despite an indicated intrinsic discount of about 72%, you have to ask: is there still an entry point here, or is the market already baking in years of future growth? With BridgeBio Pharma last closing at US$7
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027GlobeNewswire
- BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]Yahoo! Finance
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 [Yahoo! Finance]Yahoo! Finance
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027GlobeNewswire
- BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 8-K
- 1/8/26 - Form 144
- BBIO's page on the SEC website